Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dynacil
2. Fosenopril
3. Fosinil
4. Fosinopril
5. Fosinopril Sodium
6. Fosinopril, (1(s*(r*)),2 Alpha,4 Alpha)-(d-pro)-isomer
7. Fosinopril, (1(s*(r*)),2 Alpha,4 Beta)-isomer
8. Fosinopril, (1(s*(s*)),2 Alpha,4 Beta)-isomer
9. Fosinorm
10. Fositens
11. Fozitec
12. Hiperlex
13. Monopril
14. Newace
15. Sodium, Fosinopril
16. Sq 28,555
17. Sq 28555
18. Sq-28,555
19. Sq-28555
20. Sq28,555
21. Sq28555
22. Staril
23. Tenso Stop
24. Tensocardil
1. Fosinopril Sodium
2. 88889-14-9
3. Chebi:5164
4. 1217528-56-7
5. Dynacil
6. Eliten
7. Sodium;(2s,4s)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate
8. Sodium (2s,4s)-4-cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylate
9. Fosinopril Sodium- Bio-x
10. Ncgc00167432-01
11. Dsstox_cid_26621
12. Dsstox_rid_81772
13. Dsstox_gsid_46621
14. Schembl40690
15. Chembl3188382
16. Dtxsid7046621
17. Tox21_112436
18. Mfcd00897699
19. Akos015888700
20. Ac-6227
21. Bcp9000703
22. Bs-1003
23. Sq28555
24. Bf164489
25. Cas-88889-14-9
26. A842989
27. Sodium (2s,4s)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylate
28. Sodium (2s,4s)-4-cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-
29. Sodium (2s,4s)-4-cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)-(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylate
30. Sodium (2s,4s)-4-cyclohexyl-1-(2-{[2-methyl-1-(propionyloxy) Propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylate
31. Sodium(2s,4s)-4-cyclohexyl-1-(2-((2-methyl-1-(propionyloxy)propoxy)(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylate
Molecular Weight | 585.6 g/mol |
---|---|
Molecular Formula | C30H45NNaO7P |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 15 |
Exact Mass | 585.28313405 g/mol |
Monoisotopic Mass | 585.28313405 g/mol |
Topological Polar Surface Area | 113 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 857 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Fosinopril sodium |
Drug Label | Fosinopril sodium tablet, USP is the sodium salt of fosinopril USP, the ester prodrug of an angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. It contains a phosphinate group capable of specific binding to the active site of angiotensin con... |
Active Ingredient | Fosinopril sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Actavis Labs Fl; Teva; Apotex; Aurobindo Pharma; Sandoz; Invagen Pharms |
2 of 2 | |
---|---|
Drug Name | Fosinopril sodium |
Drug Label | Fosinopril sodium tablet, USP is the sodium salt of fosinopril USP, the ester prodrug of an angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. It contains a phosphinate group capable of specific binding to the active site of angiotensin con... |
Active Ingredient | Fosinopril sodium |
Dosage Form | Tablet |
Route | Oral |
Strength | 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Actavis Labs Fl; Teva; Apotex; Aurobindo Pharma; Sandoz; Invagen Pharms |
Angiotensin-Converting Enzyme Inhibitors
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
51
PharmaCompass offers a list of Fosinopril API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fosinopril manufacturer or Fosinopril supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fosinopril manufacturer or Fosinopril supplier.
PharmaCompass also assists you with knowing the Fosinopril API Price utilized in the formulation of products. Fosinopril API Price is not always fixed or binding as the Fosinopril Price is obtained through a variety of data sources. The Fosinopril Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fositens manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fositens, including repackagers and relabelers. The FDA regulates Fositens manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fositens API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fositens manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fositens supplier is an individual or a company that provides Fositens active pharmaceutical ingredient (API) or Fositens finished formulations upon request. The Fositens suppliers may include Fositens API manufacturers, exporters, distributors and traders.
click here to find a list of Fositens suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fositens DMF (Drug Master File) is a document detailing the whole manufacturing process of Fositens active pharmaceutical ingredient (API) in detail. Different forms of Fositens DMFs exist exist since differing nations have different regulations, such as Fositens USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fositens DMF submitted to regulatory agencies in the US is known as a USDMF. Fositens USDMF includes data on Fositens's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fositens USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fositens suppliers with USDMF on PharmaCompass.
A Fositens CEP of the European Pharmacopoeia monograph is often referred to as a Fositens Certificate of Suitability (COS). The purpose of a Fositens CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Fositens EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Fositens to their clients by showing that a Fositens CEP has been issued for it. The manufacturer submits a Fositens CEP (COS) as part of the market authorization procedure, and it takes on the role of a Fositens CEP holder for the record. Additionally, the data presented in the Fositens CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Fositens DMF.
A Fositens CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Fositens CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Fositens suppliers with CEP (COS) on PharmaCompass.
A Fositens written confirmation (Fositens WC) is an official document issued by a regulatory agency to a Fositens manufacturer, verifying that the manufacturing facility of a Fositens active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Fositens APIs or Fositens finished pharmaceutical products to another nation, regulatory agencies frequently require a Fositens WC (written confirmation) as part of the regulatory process.
click here to find a list of Fositens suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fositens as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fositens API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fositens as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fositens and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fositens NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fositens suppliers with NDC on PharmaCompass.
Fositens Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fositens GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fositens GMP manufacturer or Fositens GMP API supplier for your needs.
A Fositens CoA (Certificate of Analysis) is a formal document that attests to Fositens's compliance with Fositens specifications and serves as a tool for batch-level quality control.
Fositens CoA mostly includes findings from lab analyses of a specific batch. For each Fositens CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fositens may be tested according to a variety of international standards, such as European Pharmacopoeia (Fositens EP), Fositens JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fositens USP).